AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection
AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most patients with HIV and hepatitis C virus (HCV) coinfection, according to studies presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston.
HIVandHepatitis.com coverage of the HIV Research for Prevention Conference, October 28-31, in Cape Town.
This conference -- combining the previous HIV Vaccines and Microbicides meetings -- includes all aspects of HIV prevention including experimental vaccines, microbicide gels and rings, and pre-exposure prophylaxis (PrEP).
HIVandHepatitis.com coverage of IDWeek 2014, October 8-12, in Philadelphia.
Conference highlights include the HIV cascade of care, experimental antiretroviral therapies, interferon-free hepatitis C treatment, and news about other infectious diseases including Ebola virus and enterovirus D68.